Synedgen is a bio-pharmaceutical company developing novel therapies and products that reduce infection and inflammation at dermal, oral, mucosal and ophthalmic surfaces. Synedgen is using a comprehensive approach to control bacterial populations in the environment, to treat infections and to minimize infections by targeting sites where bacteria enter the human body. Synedgen was formed in 2009 through the merger of BioSTAR West LLC (Claremont, CA) and Hawaii Chitopure Inc. (Honolulu, HI). BioSTAR West had worked on biopolymer processing and polymer interactions with mammalian cells and bacteria. This research led to chemical modifications of a natural biopolymer and examination of the molecular interactions of these derivatives with tissue and bacterial pathogens. The company's technology has applications in cystic fibrosis antibiotics.
